PHARMACOLOGICAL APPROACH FOR TREATMENT OF INFLUENZA

Authors

  • Milica Simova Institute for Public Health, Skopje, Republic of North Macedonia
  • Tijana Serafimovska Faculty of Pharmacy, University “St. Cyril and Methodius“, Skopje, Republic of North Macedonia
  • Dejan Trajkov Institute of Immunobiology and Human Genetics, Faculty of Medicine, University "Ss Cyril and Methodius",Skopje, Republic of North Macedonia
  • Marija Darkovska Serafimovska Faculty of Medical Sciences, University „Goce Delcev“, Shtip, Republic of North Macedonia

Keywords:

influenza, antiviral drugs, vaccines

Abstract

Influenza is a viral disease which happens most often in the autumn and winter months. The most common symptoms that occur are fever, cold, sore throat, muscle aches, headaches, cough, weakness, and lethargy. There are several types of influenza viruses (A, B and C), of which the most common type in human are A (H1N1) and type B viruses. Influenza virus belongs to the group of enveloped viruses - it has a coating that originates from the membrane of the host cell that the virus carries with it when it leaves the cell. Hemagglutinin and neuraminidase are the two main types of glycoproteins present in the outer shell of influenza viruses. The M2 protein, which is a transmembrane channel present in the virus shell, passes through the lipid layer. Immediately below the lipid sheath is another protein called the matrix protein, or M1, which is positioned to enclose the nucleus of the virion on all sides. Inside the central nucleus of the virion are a non-structural protein and a ribonucleoprotein complex (RNP). The RNP complex consists of 8 gene segments of varying lengths, while the RNA-dependent RNA polymerase is a heterotrimer consisting of 2 polymerase bases (PB1 and PB2) and one polymerase acid subunit. All these sites are target sites for influenza medications. Methods for treatment to influenza vary depending on the severity of the disease. There are several approved medications for therapy of influenza available on the market. Neuraminidase inhibitors (oseltamivir, zanamir) are the most used medicines. To overcome the limitations of these medicines (due to rapid mutations and resistance of the virus to neuraminidase inhibitors), several attempts have been made to develop new medicines against the influenza virus. Some of them are already approved (baloxavir approved in 2018 in Japan and the United States and favipiravir - nucleoside analogue which after oral ingestion is phosphoribosylated intracellularly to be transformed into an active form) or are in an advanced (second) stage of development (pimodivir which inhibits viral replication and monoclonal antibodies). Oseltamivir due to its ease way of administration (perorally) remains the medicine of choice for the treatment of influenza. However, although neuraminidase inhibitors (especially oseltamivir) remain the medicine of choice for influenza treatment, their overuse should be avoided. Accurate selection of patients who really need this treatment is necessary. There are a number of preventive measures we can take to protect ourselves from this virus and to prevent its spread. But, vaccines remain the best option for reducing the number of infections and complications that can occur from the influenza virus.

References

Banti, C.N., N. Kourkoumelis, A.G. Hatzidimitriou, Ivi Antoniadou, A. Dimou, M. Rallis, A. Hoffmann, M. Schmidtke, K. McGuire, D. Busath, A. Kolocouris, S.K. Hadjikakou. (2020). Amantadine copper(II) chloride conjugate with possible implementation in influenza virus inhibition. Polyhedron. 185 (114590)

Billur Akkaya, Ethan M. Shevach. (2020). Regulatory T cells: Master thieves of the immune system. Cellular Immunology, 355 (104160) https://doi.org/10.1016/j.cellimm.2020.104160

Danielle Iuliano, Katherine M Roguski, Howard H Chang, David J Muscatello, Rakhee Palekar, et all. (2018). Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet, 391 (10127): 1285-1300

Delang L, Abdelnabi R, Neyts J. (2018.) Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 153:85–94.

Esposito S, (2016). Principi N. Oseltamivir for influenza infection in children: risks and benefits. Expert Rev Respir Med. 10:79–87.

Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (2018). Phase 2b Study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal iInfluenza A: TOPAZ Trial. J Infect Dis. 219:1026–34.

Furuta Y, Komeno T, Nakamura T. (2017). Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93:449–63.

Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. (2018). Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 379:913–23.

Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, et al. (2019). Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine. 40:574–82

Julia Jellusova. (2020). Metabolic control of B cell immune responses. Current Opinion in Immunology; 63: 21-28.

Krausgruber, T., Fortelny, N., Fife-Gernedl, V. et al. (2020). Structural cells are key regulators of organ-specific immune responses. Nature, 583, 296–302

Krammer, F., Palese, P. (2015). Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14, 167–182

Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. (2018). Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Investig. 38:1189–96.

McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, et al. (2017). Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model. Antimicrob Agents Chemother. 61:e01154–17.

Nguyen-Van-Tam JS. (1998). Epidemiology of influenza. In: Textbook of Influenza (Nicholson KG, Webster RG, Hay AJ, eds.). Oxford: Blackwell Science Ltd, 181–206.

Shi, M., Lin, XD., Chen, X. et al. (2018). The evolutionary history of vertebrate RNA viruses. Nature, 556:197–202

Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 23:335–44

WHO. Influenza (Seasonal). достапно на: http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

Yang T. (2019). Baloxavir marboxil: the first cap-dependent endonuclease inhibitor for the treatment of influenza. Ann Pharmacother. 53:754–9.

Downloads

Published

2021-08-16

How to Cite

Simova, M., Serafimovska, T., Trajkov, D., & Darkovska Serafimovska, M. (2021). PHARMACOLOGICAL APPROACH FOR TREATMENT OF INFLUENZA. KNOWLEDGE - International Journal , 47(4), 627–631. Retrieved from http://ikm.mk/ojs/index.php/kij/article/view/4831